Melanotan II: How a 1989 Lab Design Spawned Two FDA Drugs, and Why It Never Became One

Melanotan II sits at an odd intersection. In chemistry papers it is a textbook example of rational peptide design. Clinically it never became a drug, while two of its relatives did, and in regulatory and dermatology literature it appears mostly as an unlicensed product sold online. This Vial Post explainer separates those threads: where the molecule came from, how it engages the melanocortin receptors, what became of its relatives, and what regulators and case reports have documented.

The Vial Post covers Melanotan II only as a subject of laboratory and literature research. Nothing here describes use in people or animals.

At a Glance

• Sequence: Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-NH2, a seven-residue fragment of alpha-MSH closed into a ring by a lactam bond between Asp5 and Lys10 (Dorr 1996).
• Origin: University of Arizona, from structure-activity work on alpha-MSH by Hruby, Hadley and colleagues (Al-Obeidi 1989; Hadley & Dorr 2006).
• Receptor profile: a broad melanocortin agonist. Its activity at MC1R on melanocytes is what links it to pigmentation research.
• Regulatory status: not an approved drug in the United States. FDA has published safety concerns about compounded Melanotan II (FDA bulk substances list).

How the Molecule Was Designed

Native alpha-MSH is a linear 13-residue hormone that enzymes break down quickly. Arizona researchers had already shown that swapping methionine-4 for norleucine and L-phenylalanine-7 for its D-isomer gave a far more potent, longer-acting linear analog, [Nle4, D-Phe7]-alpha-MSH, later called NDP-MSH or afamelanotide (Al-Obeidi 1989; Hadley & Dorr 2006). The next step, published in 1989, was to use molecular-dynamics simulations to predict where a side-chain-to-side-chain bridge could lock the peptide into its active turn shape (Al-Obeidi 1989).

The team made seven cyclic lactam analogs and tested them in frog and lizard skin bioassays. The truncated 4-10 fragment with an Asp5-Lys10 lactam bridge was about 90 times as potent as alpha-MSH in the lizard assay (Al-Obeidi 1989). That compound is the one later developed as Melanotan II. Its ring is smaller than the native hormone and resists degradation, which is why later papers call it "superpotent" (Dorr 1996).

Mechanism: From Receptor to Pigment

The melanocortin system has five receptors, MC1R to MC5R, all G-protein-coupled and activated by peptides cut from the precursor proopiomelanocortin. Melanocortin ligands share a His-Phe-Arg-Trp recognition motif (Ma 2021), and Melanotan II keeps it, with D-Phe in place of Phe, inside its ring (Dorr 1996).

In melanocytes the relevant receptor is MC1R. Melanocortin receptors signal predominantly through the stimulatory G protein, Gs (Ma 2021). MC1R is expressed mainly on melanocytes and is the receptor most tied to melanogenesis (Ma 2021). Cryo-EM structures of human MC1R bound to Gs with alpha-MSH, afamelanotide and the synthetic ligand SHU9119 show how the His-Phe-Arg-Trp motif fits into the binding pocket, and point to a bound calcium ion as part of ligand recognition (Ma 2021).

The Family Tree

Melanotan II is best understood alongside two relatives that did become regulated medicines:

• Afamelanotide (NDP-MSH, once called Melanotan I): the linear Arizona analog. In a 77-person study it increased skin melanin density versus placebo, more so in people carrying common MC1R variants (Fitzgerald 2006). The FDA approved it as Scenesse, a subcutaneous implant, on October 8, 2019, for one rare light-sensitivity disorder (FDA Scenesse approval 2019).
• Bremelanotide (PT-141): described in its developer's history as an analog of Melanotan II (Hadley & Dorr 2006). The FDA approved it as Vyleesi in 2019 (FDA Vyleesi label 2019).
• Melanotan II itself: after a 1996 pilot phase I study in three volunteers, which recorded pigmentation changes alongside nausea, fatigue and spontaneous erections (Dorr 1996), development moved to its analog rather than the parent compound (Hadley & Dorr 2006).

What Regulators and Case Reports Record

Because Melanotan II has been sold outside any approval, much of its recent literature consists of safety signals rather than controlled research. A 2009 BMJ letter described changes in moles linked to an unlicensed "sun tan jab" (Langan 2009). A 2012 dermatology case report described melanoma in situ in a person using melanotan, and noted that injectable melanotropic peptides were available online "despite being unlicensed compounds with an unproven safety record" (Ong & Bowling 2012).

The FDA reached a similar conclusion in its compounding programme. Its list of bulk drug substances that may present significant safety risks notes that Melanotan II "may pose risk for immunogenicity" because of aggregation or peptide-related impurities. It also cites published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. Melanotan II now appears in the list's section for nominations that were withdrawn by their nominators (FDA bulk substances list).

Questions Readers Ask

Is Melanotan II the same as Melanotan I? No. Melanotan I is the linear NDP-MSH analog (afamelanotide). Melanotan II is the shorter cyclic lactam peptide (Al-Obeidi 1989; Hadley & Dorr 2006).

Is Melanotan II an approved drug? No. Its relatives afamelanotide and bremelanotide reached FDA approval as specific finished products in 2019 (FDA Scenesse approval 2019; FDA Vyleesi label 2019). Melanotan II did not.

Why do researchers still use it? As a stable, potent, broadly acting melanocortin agonist, it is a convenient reference compound for receptor and pigmentation-pathway experiments in cell and tissue models.

Handling in the Lab

Melanotan II is normally supplied as a lyophilized powder. Standard practice is cold storage (commonly -20 degrees C), protection from moisture and light, preparing solutions only when needed and avoiding repeated freeze-thaw cycles. Check the Certificate of Analysis for each batch.

For research and educational use only. This article is not medical advice and does not describe dosing, cosmetic or human use.